Equities

Elutia Inc

ELUT:NAQ

Elutia Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.91
  • Today's Change0.05 / 1.30%
  • Shares traded5.77k
  • 1 Year change+136.97%
  • Beta0.7416
Data delayed at least 15 minutes, as of Sep 19 2024 16:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Elutia Inc's revenues fell -49.69% from 49.19m to 24.75m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 32.90m to a larger loss of 37.66m.
Gross margin42.46%
Net profit margin-280.53%
Operating margin-131.54%
Return on assets-148.77%
Return on equity--
Return on investment-1,212.93%
More ▼

Cash flow in USDView more

In 2023, Elutia Inc increased its cash reserves by 13.46%, or 2.29m. Cash Flow from Investing totalled 14.21m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 21.76m for operations while cash generated from financing totalled 9.84m.
Cash flow per share-2.99
Price/Cash flow per share--
Book value per share-2.28
Tangible book value per share-2.63
More ▼

Balance sheet in USDView more

Elutia Inc uses little or no debt in its capital structure.
Current ratio0.7624
Quick ratio0.6842
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.